


Product Information



Ruxolitinib

Item No. 11609

CAS Registry No.: 941678-49-5
Formal Name: β R-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile
Synonym: INCB 018424
MF: C₁₇H₁₈N₆
FW: 306.4
Purity: $\geq 98\%$
Stability: ≥ 2 years at -20°C
Supplied as: A crystalline solid
UV/Vis.: λ_{max} : 216, 224, 253, 309 nm



Laboratory Procedures

For long term storage, we suggest that ruxolitinib be stored as supplied at -20°C . It should be stable for at least two years.

Ruxolitinib is supplied as a crystalline solid. A stock solution may be made by dissolving the ruxolitinib in the solvent of choice. Ruxolitinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of ruxolitinib in ethanol is approximately 13 mg/ml and approximately 5 mg/ml in DMSO and DMF.

Ruxolitinib is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ruxolitinib should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Ruxolitinib has a solubility of approximately 0.5 mg/ml in a 1:1 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Janus-associated kinases (JAKs) are cytoplasmic tyrosine kinases that are required for activating the signaling of certain cytokines and growth factor receptors.^{1,2} A JAK2 gene fusion mutation, JAK2^{V617F}, that causes unchecked activation of various growth factors and cytokines, has been linked to myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.³ Ruxolitinib is a potent ATP mimetic that inhibits both JAK1 and JAK2 with IC₅₀ values of 2.7 and 4.5 nM, respectively and is relatively less selective for JAK3 (IC₅₀ = 322 nM).³ It can block interleukin-6 (IL-6) signaling (IC₅₀ = 281 nM) and proliferation of JAK2^{V617F} Ba/F3 cells (IC₅₀ = 127 nM).⁴ In primary cultures, ruxolitinib preferentially suppresses erythroid progenitor colony formation from JAK2^{V617F} polycythemia vera patients (IC₅₀ = 67 nM) versus healthy donors (IC₅₀ > 400 nM).⁴ In a mouse model of JAK2^{V617F} MPN, 90 mg/kg ruxolitinib reduced splenomegaly, decreased circulating levels of IL-6 and TNF- α , eliminated neoplastic cells, and prolonged survival of the treated animals.⁴

References

1. Leonard, W.J. and O'Shea, J.J. JAKS AND STATS: Biological implications. *Annu. Rev. Immunol.* **16**, 293-322 (1998).
2. Yamaoka, K., Saharinen, P., Pesu, M., *et al.* The janus kinases (Jaks). *Genome Biol.* **5**(12), 1-6 (2004).
3. Verstovsek, S. Therapeutic potential of JAK2 inhibitors. *Hematology Am. Soc. Hematol. Educ. Program* **2009**(1), 636-642 (2009).
4. Quintás-Cardama, A., Vaddi, K., Liu, P., *et al.* Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. *Blood* **115**(15), 3109-3117 (2010).

Related Products

For a list of related products please visit: www.caymanchem.com/catalog/11609

WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY. NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will meet our specifications at the time of delivery.

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have **any obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 05/31/2013

Cayman Chemical

Mailing address

1180 E. Ellsworth Road
Ann Arbor, MI
48108 USA

Phone

(800) 364-9897
(734) 971-3335

Fax

(734) 971-3640

E-Mail

custserv@caymanchem.com

Web

www.caymanchem.com